The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

Table 3 Association of pre-chemotherapy cell counts and pre-chemotherapy frailty

Pre-chemotherapy	Pre-chemotherapy frailty score β (SE)
Neutrophils	0.041**
Neutrophils	(0.018)
Lymphocytes		0.043
Lymphocytes		(0.051)
Monocytes			0.069
Monocytes			(0.090)
NLR				0.044***
NLR				(0.017)
LMR					0.001
LMR					(0.002)
WBC						0.037**
WBC						(0.015)
Age 50–64	− 0.134	− 0.132	− 0.147	− 0.132	− 0.134	− 0.151
Age 50–64	(0.109)	(0.109)	(0.109)	(0.111)	(0.111)	(0.104)
Age 65+	− 0.298*	− 0.289*	− 0.281*	− 0.276*	− 0.275*	− 0.270*
Age 65+	(0.153)	(0.154)	(0.153)	(0.156)	(0.155)	(0.146)
White (yes = 1)	− 0.272*	− 0.261	− 0.230	− 0.313*	− 0.273	− 0.256*
White (yes = 1)	(0.162)	(0.162)	(0.160)	(0.165)	(0.167)	(0.153)
Married (yes = 1)	− 0.261**	− 0.245**	− 0.250**	− 0.283**	− 0.280**	− 0.248**
Married (yes = 1)	(0.113)	(0.114)	(0.113)	(0.115)	(0.115)	(0.109)
Some college or above = 1	− 0.271**	− 0.226*	− 0.233**	− 0.259**	− 0.220*	− 0.268**
Some college or above = 1	(0.116)	(0.116)	(0.116)	(0.118)	(0.118)	(0.110)
Constant	1.846***	1.902***	1.929***	1.955***	2.006***	1.730***
Constant	(0.210)	(0.228)	(0.201)	(0.203)	(0.200)	(0.221)
Observations	513	516	517	499	495	553
R-squared	0.043	0.032	0.031	0.047	0.033	0.044

Linear regression models were used to evaluate the association between cell counts and frailty, controlling for age (below 50, 50–64 versus ≥ 65 years), race (Caucasian versus others), marital status (married versus others), and education (≥ some college versus ≤ high school)
NLR neutrophil to lymphocyte ratio, LMR lymphocyte to nonocyte ratio
*Significant at 10%; **significant at 5%; ***significant at 1%

ISSN: 1465-542X